These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34907071)

  • 21. Clinical epidemiology of carbapenem-resistant enterobacteriaceae in community hospitals: a case-case-control study.
    Lee GC; Lawson KA; Burgess DS
    Ann Pharmacother; 2013 Sep; 47(9):1115-21. PubMed ID: 24259725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical characteristics of carbapenem-resistant
    Sun Y; Zheng H; Zhang JL; Yu LX; Wang B; Gao W; Cai JZ; Liu YH
    Zhonghua Er Ke Za Zhi; 2020 Aug; 58(8):640-645. PubMed ID: 32842384
    [No Abstract]   [Full Text] [Related]  

  • 23. Carbapenem and colistin resistance in children with Enterobacteriaceae infections.
    Haytoğlu Z; Gündeşlioğlu ÖÖ; Yıldızdaş D; Kocabaş E; Alabaz D; Horoz ÖÖ
    Turk J Pediatr; 2020; 62(5):778-786. PubMed ID: 33108080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global trends and hotspots in research of carbapenem-resistant Enterobacteriaceae (CRE): a bibliometric analysis from 2010 to 2020.
    Zhong H; Chen F; Li YJ; Zhao XY; Zhang ZL; Gu ZC; Yu YT
    Ann Palliat Med; 2021 Jun; 10(6):6079-6091. PubMed ID: 34237952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
    Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
    Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant Enterobacteriaceae: A Multicenter Study in China.
    Liu J; Zhang L; Pan J; Huang M; Li Y; Zhang H; Wang R; Zhao M; Li B; Liu L; Gong Y; Bian J; Li X; Tang Y; Lei M; Chen D
    J Infect Dis; 2020 Mar; 221(Suppl 2):S156-S163. PubMed ID: 32176797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Insights Into the Mechanism of Carbapenem Resistance Dissemination in Enterobacterales From a Tertiary Public Heath Setting in South Asia.
    Farzana R; Jones LS; Rahman MA; Sands K; van Tonder AJ; Portal E; Criollo JM; Parkhill J; Guest MF; Watkins WJ; Pervin M; Boostrom I; Hassan B; Mathias J; Kalam MA; Walsh TR
    Clin Infect Dis; 2023 Jan; 76(1):119-133. PubMed ID: 35412593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for the colonization or infection of carbapenem-resistant
    Lin BY; Liu JT; Jin FL
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jan; 24(1):96-101. PubMed ID: 35177183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbapenem-Resistant Enterobacteriaceae: An update narrative review from Saudi Arabia.
    Alotaibi F
    J Infect Public Health; 2019; 12(4):465-471. PubMed ID: 31060974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review.
    Qian Y; Bi Y; Liu S; Li X; Dong S; Ju M
    Ann Palliat Med; 2021 Jul; 10(7):7340-7350. PubMed ID: 34263631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.
    Trecarichi EM; Tumbarello M
    Virulence; 2017 May; 8(4):470-484. PubMed ID: 28276996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbapenem-resistant Enterobacteriaceae among kidney transplant recipients - insights on the risk of acquisition and CRE infection.
    Freire MP; Carvalho LB; Reusing JO; Spadão F; Lopes MIBF; Nahas WC; David-Neto E; Pierrotti LC
    Infect Dis (Lond); 2021 Jun; 53(6):430-439. PubMed ID: 33612056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and risk factors of carbapenem-resistant
    Aleidan FAS; Alkhelaifi H; Alsenaid A; Alromaizan H; Alsalham F; Almutairi A; Alsulaiman K; Abdel Gadir AG
    Expert Rev Anti Infect Ther; 2021 Mar; 19(3):393-398. PubMed ID: 32930620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.
    Chastain DB; White BP; Cretella DA; Bland CM
    Ann Pharmacother; 2018 May; 52(5):484-492. PubMed ID: 29239220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis.
    Zhu WM; Yuan Z; Zhou HY
    Antimicrob Resist Infect Control; 2020 Jan; 9(1):23. PubMed ID: 32005246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
    Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.
    Ni W; Han Y; Liu J; Wei C; Zhao J; Cui J; Wang R; Liu Y
    Medicine (Baltimore); 2016 Mar; 95(11):e3126. PubMed ID: 26986165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: A meta-analysis of randomised controlled trials.
    Che H; Wang R; Wang J; Cai Y
    Int J Antimicrob Agents; 2019 Dec; 54(6):809-813. PubMed ID: 31533075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.